AKI biomarkers in COVID-19 [COVID-19]
Research type
Research Study
Full title
AKI biomarkers for prediction of acute kidney injury in critically ill patients with COVID-19 and respiratory disease \n
IRAS ID
283675
Contact name
Marlies Ostermann
Contact email
Sponsor organisation
Guy's & St Thomas' NHS Foundation Hospital
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 7 months, 17 days
Research summary
In critically ill patients with COVID-19, acute kidney failure is very common. Patients with acute kidney failure have an increased risk of dying, especially if dialysis treatment is required. The latest national report shows a 75% mortality in ICU in patients with COVID-19 who needed ventilator and dialysis treatment. \n\nIn critically ill patients without COVID-19, the two urine proteins, tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth-factor binding protein 7 (IGFBP7), have been shown to predict the development of acute kidney failure before it occurs. Whether these biomarkers also work in critically ill patients with COVID-19 is unknown. \nIn this project, we plan to investigate serial changes of relevant kidney biomarkers in critically ill patients with COVID-19. The aim is to improve the knowledge about this disease, to find out whether it is possible to predict acute kidney failure better and to investigate whether these biomarkers can also predict other important outcomes. The data will be used to improve the care of patients and to guide future research studies. \n\n\n \nThe aim of this project is to explore whether urinary cell cycle arrest markers and other renal biomarkers have a role in predicting AKI in critically ill patients with COVID-19 and acute respiratory disease. The results will advance the understanding of this disease and serve to develop strategies for individualized management of this high-risk group and future intervention trials.\n
REC name
London - Brighton & Sussex Research Ethics Committee
REC reference
20/LO/0851
Date of REC Opinion
15 Jun 2020
REC opinion
Further Information Favourable Opinion